Gilead Sciences, Inc. (GILD)
Biological Products, (No Diagnostic Substances) · market cap $187.5B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-01 (est.)Phase 2 · Sacituzumab Govitecan (SG)imp 7/10
- 2026-12-15 (est.)Phase 2 · Zimberelimabimp 7/10
- 2026-12-30 (est.)Phase 2 · Remdesivir (RDV)imp 7/10
- 2026-12-31 (est.)Phase 2 · Sacituzumab Govitecanimp 7/10
- 2027-01-01 (est.)Partnershipimp 7/10
- 2027-01-12 (est.)Phase 3 · Sacituzumab Govitecanimp 9/10
- 2027-01-15 (est.)Phase 2 · Tilpisertib Fosmecarbilimp 7/10
- 2027-01-31 (est.)Phase 2 · Anti-OX40 Antibody PF-04518600imp 7/10
| Asset | Phase | Indication |
|---|---|---|
| MTX | Phase 3 | Rheumatoid Arthritis |
| Trodelvy | Approved | Triple-Negative Breast Cancer |
| Lenacapavir | Phase 3 | HIV Prevention |
| Magrolimab | Phase 3 | Myelodysplastic Syndrome |
| GS-9451 | Phase 2 | Hepatitis C, Chronic |
| KTE-C19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma |
| didanosine, ddI (drug) | Phase 3 | HIV Infections |
| efavirenz (drug) | Phase 3 | HIV Infections |
| Quemliclustat | Phase 2 | Biliary Tract Carcinoma |
| Cabotegravir Oral Tablet | Phase 3 | HIV Infections |
| CAB LA | Phase 3 | HIV Infections |
| Esmolol | Phase 2 | Atrial Fibrillation |
| GS-9451 tablet | Phase 2 | Chronic Genotype 1a or 1b HCV Infection |
| MVA.HTI | Phase 2 | HIV/AIDS |
| Sacituzumab Govitecan-Hziy plus bevacizumab | Phase 2 | NSCLC Stage IV |
| Levocarnitine | Phase 2 | HIV Infections |
| ChAdOx1.HTI | Phase 2 | HIV/AIDS |
| GS-9620 | Phase 2 | HIV/AIDS |
| Tenofovir Disoproxil Fumarate + Emtricitabine | Phase 3 | HIV Infections |
| TDF/FTC tablets | Phase 3 | HIV Infections |
Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for GILD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
